ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Dosage"

  • 2021 American Transplant Congress

    De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience

    N. Singh1, T. Le1, M. S. Naseer1, S. Asmil1, A. Palermini1, A. Qamar1, R. Chand1, S. Tandukar1, D. Aultman2, H. Shokouh-Amiri2, G. Zibari2

    1Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA, 2Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA

    *Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
  • 2021 American Transplant Congress

    Clinical Impact of Transplant Pharmacists on the Care of Solid Organ Transplant Recipients

    I. Shah1, J. Au1, A. Diamond1, N. Sifontis2, C. Ruggia-Check1

    1Temple University Hospital, Philadelphia, PA, 2Temple School of Pharmacy, Philadelphia, PA

    *Purpose: The United Network for Organ Sharing (UNOS) and Centers for Medicare and Medicaid Services (CMS) requires transplant centers to document the participation of a…
  • 2021 American Transplant Congress

    Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience

    S. Alharbi1, A. Aljedai2, D. Alkortas2

    1Pharmaceutical Care Division, KFSH&RC, riyadh, Saudi Arabia, 2Pharmaceutical Care Division, KFSH&RC, Riyadh, Saudi Arabia

    *Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…
  • 2021 American Transplant Congress

    Evaluation of Low Dose Famciclovir as Herpes Simplex Virus and Varicella Zoster Virus Prophylaxis in Cytomegalovirus Low Risk Solid Organ Transplant Recipients

    M. Cote, A. Cubley, C. Rogers, S. Shao, C. N. Kotton

    Massachusetts General Hospital, Boston, MA

    *Purpose: Famciclovir is recommended for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low risk (both donor and recipient CMV seronegative)…
  • 2021 American Transplant Congress

    Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients

    A. Diamond1, N. Agarwal2, A. Younas2, N. Sifontis2, J. Au1, C. Ruggia-Check1

    1Pharmacy, Temple University Hospital, Philadelphia, PA, 2Pharmacy, Temple University School of Pharmacy, Philadelphia, PA

    *Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…
  • 2021 American Transplant Congress

    Avoiding Tacrolimus Under- and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial

    M. I. Francke1, L. M. Andrews2, H. L. Le2, J. van de Wetering1, M. C. Clahsen-van Groningen3, T. van Gelder4, R. H. van Schaik5, B. van der Holt6, B. C. de Winter2, D. A. Hesselink1

    1Internal medicine, nephrology and transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 2Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 3Pathology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 4Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands, 5Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 6Hematology, Erasmus MC, University Medical Center, Rotterdam, Netherlands

    *Purpose: Bodyweight-based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meagre 38% of patients is…
  • 2020 American Transplant Congress

    Assessment of Time to Therapeutic Tacrolimus Levels Following Renal Transplantation in a Non-Weight-Based Dosing Model

    J. Banbury1, A. Dodson1, C. Lin2, K. Gutierrez1

    1University of Alabama at Birmingham Hospital, Birmingham, AL, 2Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL

    *Purpose: The optimal initial dose for tacrolimus (TAC) after renal transplant (RT) remains controversial with limited evidence comparing weight-based and conservative strategies. Recent literature suggests…
  • 2020 American Transplant Congress

    Less Bleeding Associated with Apixaban versus Other Direct Acting Oral Anticoagulation in Solid Organ Transplant Recipients

    M. Thornberg1, J. Scheffert1, D. Jennings2, J. Hedvat1, N. Lange1, H. Robbins3, D. Salerno1

    1NewYork-Presbyterian Hospital, Department of Pharmacy, New York, NY, 2Long Island University School of Pharmacy, Brooklyn, NY, 3Columbia Irving University Medical Center, Department of Medicine, New York, NY

    *Purpose: Owing to their fixed dosing and favorable drug interaction profiles, direct acting oral anticoagulants (DOACs) have supplanted warfarin as the standard of care for…
  • 2020 American Transplant Congress

    A Single Centre Experience of Conversion from Immediate Release Tacrolimus (IR-tac) to Extended Release Envarsus

    S. Chong1, E. Kent2, C. Beligaswatta2, P. Gudka2, C. Magee2, M. Harber2, R. Motallebzadeh1, G. Jones2

    1Centre for Transplantation, Department of Renal Medicine, University College London & Royal Free London NHS Foundation Trust​, London, United Kingdom, 2Department of Renal Medicine, University College London & Royal Free London NHS Foundation Trust​, London, United Kingdom

    *Purpose: IR-Tac is first line maintenance immunosuppression in kidney transplant recipients. Its rapid absorption of 1-2 hours can lead to peak levels (Tmax ) within…
  • 2020 American Transplant Congress

    Impact of Donor Race on Tacrolimus Dose Requirement for Liver Transplant Recipients

    N. Nesselhauf1, S. January1, J. Hagopian1, K. Progar1, A. Khan2

    1Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, 2Surgery, Washington University School of Medicine, St. Louis, MO

    *Purpose: It is well described that there is interpatient variability in tacrolimus dose requirements among transplant recipients. CYP3A5 plays a role in this variability. Black…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences